(MedPage Today) — Intercept Pharmaceuticals has pulled obeticholic acid (Ocaliva) from the U.S. market as a treatment for primary biliary cholangitis (PBC) after the FDA requested its removal and placed ongoing trials on clinical hold.
The move…
Source link : https://www.medpagetoday.com/gastroenterology/generalhepatology/117441
Author :
Publish date : 2025-09-12 16:37:00
Copyright for syndicated content belongs to the linked Source.
